









Markets
/
Stocks
/
nasdaq-cccc
/

C4 Therapeutics Inc

CCCC

1.820USD

+0.110+6.43%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

135.00MMarket Cap

LossP/E TTM



C4 Therapeutics Inc

1.820

+0.110+6.43%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of C4 Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

C4 Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 76 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.86.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

C4 Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

76 / 392

Overall Ranking

197 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

C4 Therapeutics Inc Highlights

StrengthsRisks

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

Growing

The company is in a growing phase, with the latest annual income totaling USD 35.58M.

Overvalued

The company’s latest PE is -1.09, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 70.34M shares, increasing 19.83% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 191.82K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.857

Target Price

+476.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of C4 Therapeutics Inc is 7.09, ranking 160 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.23M, representing a year-over-year decrease of 26.90%, while its net profit experienced a year-over-year decrease of 30.41%.

Score

Industry at a Glance

Previous score

7.09

Change



Financials

6.22

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.16

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.25

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

C4 Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of C4 Therapeutics Inc is 7.38, ranking 129 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.09, which is -60.52% below the recent high of -0.43 and -279.21% above the recent low of -4.12.

Score

Industry at a Glance

Previous score

7.38

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of C4 Therapeutics Inc is 8.75, ranking 61 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 29.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.857

Target Price

+421.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

C4 Therapeutics Inc

CCCC

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of C4 Therapeutics Inc is 6.43, ranking 249 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.30 and the support level at 1.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.19

Change

0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.056

Sell

RSI(14)

39.352

Neutral

STOCH(KDJ)(9,3,3)

21.706

Neutral

ATR(14)

0.129

Low Volatility

CCI(14)

-112.658

Sell

Williams %R

75.940

Sell

TRIX(12,20)

-0.549

Sell

StochRSI(14)

55.573

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.862

Sell

MA10

1.941

Sell

MA20

2.070

Sell

MA50

2.208

Sell

MA100

2.332

Sell

MA200

2.138

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of C4 Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 70.90%, representing a quarter-over-quarter decrease of 34.85%. The largest institutional shareholder is Steven Cohen, holding a total of 8.48M shares, representing 8.75% of shares outstanding, with 2522.18% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Point72 Asset Management, L.P.

Star Investors

8.48M

RA Capital Management, LP

8.00M

Lynx1 Capital Advisors LLC

7.10M

Soleus Capital Management, L.P.

7.05M

+1.07%

OrbiMed Advisors, LLC

5.24M

-23.35%

Betta investment Hong Kong Ltd

4.87M

-12.45%

Morgan Stanley & Co. LLC

4.86M

+54.22%

Wasatch Global Investors Inc

Star Investors

4.85M

-34.64%

The Vanguard Group, Inc.

Star Investors

3.19M

+5.75%

BofA Global Research (US)

2.05M

+2.25%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of C4 Therapeutics Inc is 3.35, ranking 147 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.96. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.